Sareum

August 14, 2020

Bristol hopes to Tyk the psoriasis box

The company’s massive clinical programme with BMS-986165 is set to deliver its first pivotal data later this year.

April 30, 2019

Lilly scraps two research assets, leaving few rivals behind

September 17, 2018

Tyk2 reaches tipping point

Bristol-Myers Squibb is ahead in a new oral class that could bring similar efficacy to current injectables for autoimmune diseases – but Pfizer seems less keen.

October 01, 2014

Therapy focus – Leukaemia opportunity gives FLT a chance to take flight

August 09, 2011

Sareum

Bristol hopes to Tyk the psoriasis box

Lilly scraps two research assets, leaving few rivals behind

Tyk2 reaches tipping point

Therapy focus – Leukaemia opportunity gives FLT a chance to take flight

Therapeutic focus - Roche places big bet on novel chemotherapy enhancers

Latest Reports

Evaluate Vantage Pharma, Biotech & Medtech Half-Year Review 2020

Evaluate Vantage COVID-19 Report

Editor's Picks

Finding the next Vertex

Clinical setback lays bare Vertex’s weakness

SITC 2020 – embargo snafu triggers the first movers

Biopharma buyouts still pricey

More biotechs test the third way to market